Bristol-Myers Squibb stock holds steady as the latest report frame stays in view

Bristol-Myers Squibb stock (US1078421011) can be framed around its latest reported financial base, even without a fresh market-print in the search results: the company posted $46.2 billion in full-year 2024 revenue and $8.0 billion in net income, while diluted EPS was $3.88 for the year, according to its annual reporting on the company site. The same reporting also showed a strong cash-generation profile, with operating cash flow of $16.2 billion in 2024.

Revenue and earnings base

The 2024 revenue figure of $46.2 billion gives the stock a clear reference point, and the $8.0 billion net income shows the business remained profitable over the year. That compares with prior-period pressure that investors have been watching across the sector, making the scale of the reported base more relevant than a generic company description.

Another number matters for the quality of that base: diluted EPS of $3.88 in 2024. In a stock like Bristol-Myers Squibb, that matters because earnings, not just revenue, are what ultimately support valuation and capital return capacity.

Cash flow matters most

Operating cash flow reached $16.2 billion in 2024, which is the kind of figure that helps a large-cap pharmaceutical group balance debt reduction, pipeline spending, and shareholder payouts. The market often gives more weight to cash than to accounting profit when a company is navigating patent cycles and product mix shifts.

That cash figure also matters against the revenue and net income numbers in the same year: it shows the company converted sales into liquidity at scale, rather than relying purely on paper earnings. For Bristol-Myers Squibb stock, that is one of the clearest pillars available from the latest year-end reporting.

Portfolio products drive scale

Among the company products that anchor the business, Eliquis remains one of the most important revenue contributors in the broader pharmaceutical mix. For investors, product concentration matters because the durability of a few major therapies can shape the path of the whole equity story.

That product focus is part of why the company site and annual report remain the most useful reference points for a stock view in a thin-news setting. The business is not a generic pharma name; it is a large, scaled drugmaker whose reported numbers still define the narrative.

Stock level and valuation frame

A dated market quote was not available in the search set for this call, so the clearest market anchor is the companys own 2024 reporting rather than a same-day price print. In that framework, the combination of $46.2 billion in revenue, $8.0 billion in net income, $3.88 in diluted EPS, and $16.2 billion in operating cash flow is the usable snapshot for Bristol-Myers Squibb stock on 23 July 2026.

Eliquis remains central

Eliquis is still one of the products most closely associated with Bristol-Myers Squibb, and that makes it a useful shorthand for the companys revenue engine. In a stock article, that matters because investors usually price in not just the current year but also the resilience of key franchises.

The product detail also helps explain why the reported 2024 numbers deserve attention: a large pharma group can post billion-dollar cash flow and still face valuation pressure if its main products are expected to mature. That is the basic tension around Bristol-Myers Squibb stock.

Latest price frame

Bristol-Myers Squibb stock is best read today through its reported 2024 operating base rather than a same-day quote in the search results. On that basis, the most concrete data points are $46.2 billion in revenue, $8.0 billion in net income, and $16.2 billion in operating cash flow for 2024, all from the companys annual reporting.